SNF Based Dialysis Market: as Fresenius Medical Care secures FDA clearance for a next-generation hemodiafiltration platform positioned to become the new US standard of care while US Renal Care continues opening new centres specifically targeting rural and underserved populations, the two largest dialysis operators are pursuing complementary strategies, one betting on treatment technology advancement, the other on geographic access expansion, both of which directly extend the infrastructure and clinical capability available to skilled nursing facility dialysis programmes specifically.

The global SNF based dialysis market size was USD 3.42 Billion in 2025 and is expected to register a revenue CAGR of 6.1% during the forecast period. Market revenue growth is driven by factors such as aging end-stage renal disease population expanding the skilled nursing facility resident population requiring on-site dialysis access, treatment technology advancement improving dialysis efficacy and expanding the clinical case for on-site SNF programmes, and dialysis operator geographic expansion extending SNF dialysis programme access into underserved regions. The first driving factor is the aging end-stage renal disease population, which directly expands the skilled nursing facility resident population requiring reliable, accessible on-site or satellite dialysis services rather than off-site transport to conventional dialysis centres. In-centre haemodialysis accounts for a substantial share of total 2025 market revenue, reflecting this modality's continued centrality to the SNF resident population's treatment needs. The second driving factor is treatment technology advancement, as next-generation dialysis platforms improve treatment efficacy and expand the clinical case for on-site SNF dialysis programmes over off-site transport. The third driving factor is dialysis operator geographic expansion, as the largest operators extend SNF dialysis programme access into rural and previously underserved regional markets. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single dialysis operator's expansion of its SNF chain management service agreements converts one successful facility partnership into a template that the same operator can replicate across additional facilities within the same chain relationship, which lets the operator capture growing SNF dialysis programme revenue without needing to separately win each individual facility relationship from scratch. Because a large SNF chain operator managing multiple facilities benefits from standardising its dialysis service partnership across its full facility network rather than negotiating separate arrangements at each individual location, a dialysis operator that successfully establishes one facility partnership within a chain gains a meaningfully lower-friction path to expanding that same relationship across the chain's other facilities, so successful chain-level partnerships compound faster than facility-by-facility sales alone would allow. As a result, demand and revenue share are concentrating around dialysis operators with the strongest SNF chain-level partnership relationships, and the forecast reflects this chain-replication dynamic as a distinct driver of operator-level market share concentration. For instance, in April 2025, US Renal Care opened 12 new dialysis centres across Texas and Arizona, focusing specifically on improving dialysis access in rural and Hispanic-majority populations, extending the kind of geographic access expansion that supports SNF dialysis programme availability in previously underserved regional markets. These are some of the key factors driving revenue growth of the market.

Because the CMS ESRD Prospective Payment System sets the base per-treatment reimbursement rate that dialysis operators receive for the substantial majority of their SNF and conventional dialysis patient population, modest annual market basket rate updates continue to create genuine margin pressure for operators managing rising labour and supply costs against a comparatively slower-growing reimbursement base.

Clinical staffing shortages specific to dialysis nursing and technician roles are a second constraint, since expanding SNF dialysis programme capacity requires qualified dialysis nursing and technician staff that remain in documented short supply in many regional labour markets, which can constrain how quickly an operator can actually open new SNF programme sites even where facility partnership agreements and reimbursement support already exist.

SNF facility infrastructure and space constraints are a third constraint, since not every skilled nursing facility has adequate physical space or water treatment infrastructure to support on-site haemodialysis units, which can require capital investment in facility modification before an on-site dialysis programme becomes operationally viable.

These factors substantially limit SNF based dialysis market growth over the forecast period.

The clearest driver of demand is the aging end-stage renal disease population, which directly expands the skilled nursing facility resident population requiring reliable, accessible on-site or satellite dialysis services rather than off-site transport to conventional dialysis centres. A skilled nursing facility resident requiring dialysis who must be transported off-site for treatment faces genuine care coordination burden and clinical risk during transport, so on-site or satellite dialysis access directly addresses this care continuity challenge for an aging, medically complex resident population. In-centre haemodialysis accounts for a substantial share of total 2025 market revenue, and CMS's ESRD Prospective Payment System sets the foundational per-treatment reimbursement rate underlying SNF dialysis programme financial viability across the covered patient population. The effect on the market is that baseline SNF dialysis demand tracks the aging ESRD population and skilled nursing facility census trends directly, providing a demand base tied to well-documented demographic patterns. These are some of the key factors driving revenue growth of the market.

The second driver is treatment technology advancement, as next-generation dialysis platforms improve treatment efficacy and expand the clinical case for on-site SNF dialysis programmes over off-site transport to conventional dialysis centres. A dialysis platform that delivers a genuinely more effective treatment modality, such as high-volume hemodiafiltration, strengthens the clinical justification for bringing that treatment capability directly to the SNF resident population rather than requiring transport to a facility that has the newer technology. In June 2025, Fresenius Medical Care received FDA 510(k) clearance for its new hemodiafiltration-capable 5008X CARE system, with the company positioning high-volume hemodiafiltration to become the new standard of care for kidney replacement therapy in the United States, with full commercial launch following in 2026. The effect on the market is that on-site SNF dialysis programme value proposition strengthens as the newest treatment technology becomes available for on-site deployment rather than remaining confined to conventional dialysis centre settings. These are some of the key factors driving revenue growth of the market.

Fresenius Medical Care's 5008X CARE system, FDA-cleared in June 2025, is positioned by the company to become the new US standard of care for kidney replacement therapy with full commercial launch in 2026. As next-generation dialysis technology reaches SNF-deployable platforms, the clinical case for on-site programmes over off-site transport strengthens correspondingly.

The third driver is dialysis operator geographic expansion, as the largest operators extend SNF dialysis programme access into rural and previously underserved regional markets that have historically lacked adequate on-site dialysis infrastructure. A skilled nursing facility located in a rural or historically underserved market often faces genuine access barriers to dialysis services given the concentration of conventional dialysis centres in more densely populated areas, so operator geographic expansion specifically targeting these underserved markets directly addresses an access gap rather than simply adding incremental capacity in already well-served regions. In April 2025, US Renal Care opened 12 new dialysis centres across Texas and Arizona, focusing specifically on improving dialysis access in rural and Hispanic-majority populations, extending the kind of geographic access expansion that supports broader SNF dialysis programme availability in previously underserved regional markets. The effect on the market is that SNF dialysis programme geographic coverage continues expanding into markets that operators have historically underserved, extending the category's addressable facility population. These are some of the key factors driving revenue growth of the market.

However, the SNF based dialysis market faces severe adoption constraints from Medicare ESRD Prospective Payment System reimbursement rate pressure limiting operator margin expansion, and clinical staffing shortages specific to dialysis nursing and technician roles constraining SNF programme expansion capacity.

Because the CMS ESRD Prospective Payment System sets the base per-treatment reimbursement rate that dialysis operators receive for the substantial majority of their SNF and conventional dialysis patient population, modest annual market basket rate updates continue to create genuine margin pressure for operators managing rising labour and supply costs, including newer technology investments like Fresenius's 5008X CARE platform, against a comparatively slower-growing reimbursement base.

Clinical staffing shortages specific to dialysis nursing and technician roles compound this, since expanding SNF dialysis programme capacity, including US Renal Care's continued geographic expansion, requires qualified dialysis nursing and technician staff that remain in documented short supply in many regional labour markets, which can constrain how quickly an operator can actually open new SNF programme sites even where facility partnership agreements and reimbursement support already exist.

SNF facility infrastructure and space constraints are the third constraint, since not every skilled nursing facility has adequate physical space or water treatment infrastructure to support on-site haemodialysis units, which can require capital investment in facility modification before an on-site dialysis programme becomes operationally viable.

These factors substantially limit SNF based dialysis market growth over the forecast period.

Based on modality, the global SNF based dialysis market is segmented into in-centre haemodialysis, peritoneal dialysis, and home haemodialysis. In-centre haemodialysis holds the largest revenue share, because on-site SNF haemodialysis units represent the most common treatment approach for the skilled nursing facility resident population's dialysis needs, which suits a market where the most institutionally established modality commands the largest revenue category. Peritoneal dialysis remains an important, growing alternative modality for appropriate SNF resident candidates. Home haemodialysis is expected to register the fastest revenue growth rate in the global SNF based dialysis market over the forecast period, driven by continued care model innovation extending home-based treatment concepts into supported long-term care settings.

Based on service type, the global SNF based dialysis market is segmented into on-site SNF dialysis unit, satellite dialysis services, mobile or transport dialysis coordination, and care management and clinical support services. On-site SNF dialysis unit holds the largest revenue share, because it eliminates the care coordination burden and clinical risk associated with off-site patient transport, which ties directly back to the aging ESRD population access need described in the market's primary demand driver. Satellite dialysis services are expected to register a significant revenue growth rate in the global SNF based dialysis market over the forecast period, driven by operators like US Renal Care extending satellite service models into newly opened regional markets.

Based on payer, the global SNF based dialysis market is segmented into Medicare, Medicaid, and private insurance and self-pay. Medicare holds the largest revenue share, reflecting the ESRD population's near-universal Medicare eligibility under US law regardless of age, and the ESRD Prospective Payment System's role as the foundational reimbursement mechanism for the substantial majority of SNF dialysis patients. Private insurance and self-pay is expected to register a moderate revenue growth rate in the global SNF based dialysis market over the forecast period, reflecting the initial 30-month coordination period before Medicare becomes the primary payer for newly diagnosed ESRD patients.

Based on regional analysis, the SNF based dialysis market in North America accounted for largest revenue share in 2025. The United States leads because CMS's ESRD Prospective Payment System and the scale of the US skilled nursing facility sector create the deepest and most structurally supported SNF dialysis demand globally, and because Fresenius Medical Care, DaVita, and US Renal Care all maintain their primary commercial presence in the US market. US Renal Care's April 2025 Texas and Arizona expansion and Fresenius's June 2025 5008X CARE FDA clearance both specifically reinforce the depth of ongoing US market investment. The concentration of CMS reimbursement policy development in the country also means new SNF dialysis payment and coverage frameworks typically establish in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent significant national markets within Europe, anchored by Fresenius Medical Care's German headquarters and B. Braun Avitum's established European dialysis service presence. The result is steady rather than rapid growth, shaped more by national health system long-term care reimbursement structures than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan and China represent two of the largest national markets within the region, driven by expanding aging population and long-term care infrastructure investment. The region's rapidly scaling long-term care sector leaves considerably more room for growth than in the already SNF-dialysis-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding long-term care infrastructure driving early SNF dialysis demand growth. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the dialysis machine components and water treatment equipment that Latin American SNF dialysis programmes depend on, an effect expected to run through 2026 and slow SNF based dialysis adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding long-term care infrastructure investment and the UAE's regional distribution hubs represent the primary investment centres for SNF based dialysis adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the long-term care dialysis infrastructure needed to support advanced SNF programmes at scale.